Research Focus

Former Employee. MEDICINE; Research Stdy Asst II

Recent additions – View all

1. Pharmacogenomic analysis of a randomized phase II trial (BOND 2) of cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer

   Meeting Abstract

   Zhang, W.; Yang, D.; Capanu, M.; Hollywood, E.; Lue-Yat, M.; Borucka, E.; Azuma, M.; Gordon, M.; Saltz, L.; Lenz, H.
   Journal of Clinical Oncology (2007)

   Fulltext@MSK | Save
2. Molecular markers associated with response and clinical outcome to cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer (BOND2)

   Meeting Abstract

   Azuma, M.; Yang, D.; Carpanu, M.; Hollywood, E.; Lue-Yat, M.; Zhang, W.; Danenberg, K. D.; Danenberg, P. V.; Saltz, L.; Lenz, H.
   Journal of Clinical Oncology (2007)

   Fulltext@MSK | Save